Dr. Ed Mascioli is appointed CEO, joined by Independent Directors Drs. Larry Miller and Ron Cohen. ZWI utilizes polycarboxybetaine, a novel polymer, for conjugates with improved safety. The lead program, ZWI-001, targeting hyperuricemia in severe gout, shows promise.